Remove 2025 Remove Blood Pressure Remove Hypertension
article thumbnail

Study Links Microaggressions to Higher Post-Birth Blood Pressure

DAIC

Photo: American Heart Association tim.hodson Tue, 01/14/2025 - 16:05 Jan. 9, 2025 Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond, according to new research published in Hypertension , a peer-reviewed journal of the American Heart Association.

article thumbnail

New Study to Examine Hypercortisolism in Resistant Hypertension

DAIC

tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

article thumbnail

Medtronic Presents New Data, Clinical Milestones at CRT 2025

DAIC

tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.

article thumbnail

FDA Approves Updated Label for Tryvio (aprocitentan)

DAIC

tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.

article thumbnail

Data Demonstrates Favorable Impact of AVIM Therapy on Diastolic Dysfunction

DAIC

tim.hodson Fri, 02/14/2025 - 14:32 Feb. tim.hodson Fri, 02/14/2025 - 14:32 Feb. The presentation,"Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction,"was deliveredby Marat Fudim, M.D., Advanced Heart Failure Cardiologist, Duke Health on Feb.

article thumbnail

Equating Office and Ambulatory Blood Pressure

Hypertension Journal

Hypertension, Volume 82, Issue 2 , Page 161-165, February 1, 2025.

article thumbnail

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat

DAIC

tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. The Company anticipates initiating the trial in the first quarter of 2025.